“Darnitsa” produced 173 million packages of medicines in 2022

Despite the difficult conditions of wartime, the domestic pharmaceutical company “Darnitsa” managed to improve its business results: while in 2021 every seventh package of medicine sold in pharmacies was produced by “Darnitsa” , in 2022 it was every sixth package.*

“Darnitsa” remains the leader of Ukraine’s retail pharmaceutical market of medicinal products in its natural form.* Last year, the company produced 173 million packages of drugs, almost at the level of the previous pre-war year. This allowed “Darnitsa” to capture 15.7%** of the Ukrainian pharmaceutical market — twice as much as the nearest competitor.

The company has been present on the market for more than 90 years and produces medicines of 180 brands in 15 different forms - in the form of tablets, solutions, drops, powders, etc. In 2022, “Darnitsa” produced about 19 million packages of ampoules, 9 million packages of infusion solutions, and 130 million packages of tablets and capsules. The company continued to operate from the first days of the full-scale war. In March, it produced 60% of the pre-war volume of medicines, and since April it has returned to the pre-war volume of production in full.

Despite the full-scale war, “Darnitsa” plant continues to adhere to high international quality standards for drug production. In April last year, the company received a certificate of compliance with the requirements of the Good Manufacturing Practice (GMP) of the Australian regulatory body for sterile production. In October, “Darnitsa” once again successfully passed the inspection of the State Service of Ukraine for Medicinal Products and Drug Control and received updated GMP compliance certificates. In December, the company passed an inspection from the regulatory body of Kazakhstan for all production sites.

“This year, the production of medicines at “Darnitsa” plant is a collection of small stories of courage and dedication to the cause. In March, some employees covered tens of kilometers every day to get to work when public transport was not working. Some not only worked, but also lived with their children in a bomb shelter on the territory of the enterprise. Section managers worked on production lines, and office workers loaded trucks in the warehouse. Everyone did what was necessary, not what was written in the job instructions, because they understood it was necessary to provide the country with medicine. The year was extremely difficult for everyone in our country. But I can proudly state that our glorious team has endured and continues to overcome all challenges with dignity. We have ambitious plans for the next year and the courage to implement them,” said Liudmyla Denesiuk, director of the production department of the Darnitsa pharmaceutical company.

Note

PrJSC Pharmaceutical Company “Darnitsa” was founded in 1930. Since 1998, “Darnitsa” has been the leader in Ukraine in terms of volume of production. Strategic areas of portfolio development – cardiology, neurology, pain management.

*according to Proxima Research, based on the results of January-November 2022.

** in terms of volume, according to Proxima Research, based on the results of January-November 2022.